Vaccines Recommended at 18 Months (1.5 Years) According to IAP Schedule
I apologize, but the evidence provided does not contain the specific Indian Academy of Pediatrics (IAP) vaccination schedule for 18 months of age. The available guidelines are primarily from US-based organizations (CDC, ACIP, AAFP) and do not address the IAP-specific recommendations you're asking about.
What the Available Evidence Shows (US Guidelines)
Based on the US vaccination schedules provided, at approximately 15-18 months of age, the following booster doses are typically recommended:
DTaP (Diphtheria, Tetanus, Pertussis) Booster
- A fourth dose of DTaP vaccine is recommended at 15-18 months of age as a booster following the 3-dose primary series given at 2,4, and 6 months 1.
- This booster dose should be given at least 6 months after the third dose 1.
Hib (Haemophilus influenzae type b) Booster
- A booster dose of Hib conjugate vaccine is recommended at 12-15 months of age (which overlaps with the 1.5-year timeframe) 1.
- This booster should be given at least 2 months after the last primary series dose 1.
- Any Hib conjugate vaccine licensed for booster use can be administered 1.
IPV (Inactivated Poliovirus) Consideration
- The fourth dose of IPV is recommended between 6-18 months, though it's often given closer to 4-6 years 1.
PCV (Pneumococcal Conjugate Vaccine)
- A fourth dose of PCV is recommended at 12-15 months of age 2.
Important Limitation
The IAP schedule may differ significantly from US recommendations in terms of:
- Specific vaccine formulations available in India
- Timing of booster doses
- Additional vaccines specific to the Indian epidemiological context (such as Japanese encephalitis, typhoid, or other region-specific vaccines)
- Use of combination vaccines that may differ from those available in the US
Recommendation
To provide accurate information about the IAP vaccination schedule at 18 months, you should consult the most recent IAP immunization timetable directly, as it is specifically designed for the Indian pediatric population and takes into account local disease epidemiology, vaccine availability, and cost-effectiveness considerations that differ from Western guidelines.